|Bid||0.8785 x 3200|
|Ask||0.8920 x 900|
|Day's range||0.8400 - 0.8979|
|52-week range||0.8300 - 3.7000|
|Beta (5Y monthly)||3.71|
|PE ratio (TTM)||N/A|
|Earnings date||04 May 2023 - 08 May 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||5.33|
With the business potentially at an important milestone, we thought we'd take a closer look at Ocugen, Inc.'s...
Investors were pleased, if not overwhelmingly so, with Ocugen's (NASDAQ: OCGN) latest set of quarterly results on Tuesday. The biotech published its fourth-quarter and full-year figures that morning, in addition to providing a business update. Ocugen is a clinical-stage biotech that has no revenue at the moment.
Joining me today are Ocugen's chairman, CEO, and co-founder, Dr. Shankar Musunuri, who will provide a business update; and our chief accounting officer and senior vice president of finance, Jessica Crespo, who will provide more detail on our financial results. This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties.